Table 5.
Subgroup comparison within MCI population
| Predicted label | Group 1 nonprogressors |
Group 3 |
Group 2 progressors |
Group 4 |
|---|---|---|---|---|
| n = 196 | n = 35 | n = 214 | n = 29 | |
| Demographics | ||||
| Observed label: nonprogressors/progressors | 186/17 | 31/6 | 95/120 | 18/11 |
| Age, years (SD) | 66.8 (6.8)b | 68.5 (7.8) | 70.0 (6.9)a | 68.1 (6.1) |
| Females, n (%) | 52 (28)b | 12 (32) | 105 (49)a,d | 8 (28)b |
| Level of education (SD) | 5.0 (1.3) | 5.1 (1.4) | 5.1 (1.4) | 5.6 (1.5) |
| Time to progression (SD), yrs | 2.1 (0.8) | 2.7 (2.0) | 2.3 (1.4) | 2.2 (1.2) |
| Global cognition | ||||
| MMSE score (SD) | 26.8 (2.5)b | 27.2 (2.1) | 26.1 (2.5)a | 27.1 (1.9) |
| APOE genotype | ||||
| APOE ε4 carriers, n (%) | 57 (31)b,c | 20 (61)a | 146 (77)a | 15 (58)a |
| CSF biomarkers | ||||
| CSF Aβ1-42 (SD), pg/ml | 1100.1 (11.1)b,c,d | 722.4 (26.0)a,b,d | 636.8 (10.8)a,c | 551.5 (29.3)a,c |
| CSF tau (SD), pg/ml | 327.3 (17.1)b | 250.0 (40.0)b | 707.6 (16.6)a,c,d | 288.7 (45.2)b |
| CSF Ptau (SD), pg/ml | 52.4 (26.4)b | 43.2 (14.8)b | 92.9 (31.0)a,c,d | 48.5 (14.0)b |
| MRI biomarkers | ||||
| MTA, median (IQR) | 0.5 (0-1) | 1.0 (0-1.5) | 1.0 (0-1.5) | 0.5 (0.5-1.9) |
| PCA, median (IQR) | 1.0 (0-1) | 1.0 (0-1) | 1.0 (0-1) | 1.0 (0-1) |
| GCA, median (IQR) | 1.0 (0-1) | 1.0 (0-1) | 1.0 (1-1) | 1.0 (0-1) |
Comparison between different CSF profiles as identified by the CART analysis. Data are mean (SD), unless otherwise specified. Kruskal-Wallis test or chi square test was used when applicable. a: P < .05 different from group 1; b: P < .05 different from group 2; c: P < .05 different from group 3; d: P < .05 different from group 4.
Abbreviations: AD, Alzheimer's disease; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; Aβ42, amyloid β 1-42; tau, total tau; Ptau, tau phosphorylated at threonine 181; MRI, magnetic resonance imaging; MTA, medial temporal lobe atrophy; PCA, Posterior Cortical Atrophy; GCA, global cortical atrophy; SD, standard deviation; IQR, interquartile range.